A study provided an overview of the use of amifampridine (brand names  Firdapse and the recently approved Ruzurgi), along with other treatment choices for Lambert-Eaton myasthenic syndrome, including those for resistant muscle weakness. The review study, “Recent Advances and Therapeutic Options in Lambert-Eaton Myasthenic Syndrome,” was published…
Lambert-Eaton myasthenic syndrome (LEMS) has a similar prevalence and incidence in the U.S. compared with European populations, and most patients get better with therapy, particularly with 3,4-DAP – the active ingredient in Firdapse – a nationwide study using patient…
Lambert-Eaton myasthenic syndrome (LEMS) can develop as an immune-related adverse event caused by treatment with the anti-cancer therapy Opdivo (nivolumab), according to a case report. The study describes the case of a 73-year-old Japanese woman who started to…
Antibodies that recognize a protein called SOX2Â that are specific markers of small cell lung cancer (SCLC)Â could be used to identify patients with Lambert-Eaton myasthenic syndrome (LEMS) who have this type of cancer, a study reports. The study, “The utility of anti-SOX2 antibodies for cancer…
Get regular updates to your inbox.